Maplight Therapeutics (NASDAQ:MPLT) Insider James Woodruff Lillie Sells 22,082 Shares

Maplight Therapeutics, Inc. (NASDAQ:MPLT) insider James Woodruff Lillie sold 22,082 shares of the firm’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $12.54, for a total transaction of $276,908.28. Following the sale, the insider owned 202,380 shares in the company, valued at approximately $2,537,845.20. This trade represents a 9.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

James Woodruff Lillie also recently made the following trade(s):

• On Thursday, May 7th, James Woodruff Lillie sold 721 shares of Maplight Therapeutics stock. The shares were sold at an average price of $28.28, for a total value of $20,389.88.
• On Wednesday, May 6th, James Woodruff Lillie sold 24,811 shares of Maplight Therapeutics stock. The shares were sold at an average price of $28.76, for a total value of $713,564.36.

Maplight Therapeutics Trading Up 3.1%

MPLT opened at $12.94 on Wednesday. The stock has a market capitalization of $551.48 million and a P/E ratio of -0.32. The stock has a 50-day moving average price of $30.01 and a 200-day moving average price of $24.84. Maplight Therapeutics, Inc. has a 12-month low of $9.10 and a 12-month high of $40.43.

Maplight Therapeutics (NASDAQ:MPLT) last released its earnings results on Thursday, May 14th. The company reported ($1.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.43). On average, equities research analysts predict that Maplight Therapeutics, Inc. will post -5.22 EPS for the current year.

Institutional Investors Weigh In On Maplight Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Strs Ohio bought a new stake in Maplight Therapeutics in the 4th quarter worth $53,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Maplight Therapeutics during the fourth quarter worth about $70,000. New York State Common Retirement Fund purchased a new stake in shares of Maplight Therapeutics during the fourth quarter worth about $93,000. MetLife Investment Management LLC bought a new stake in shares of Maplight Therapeutics in the fourth quarter worth about $172,000. Finally, Walleye Capital LLC bought a new stake in shares of Maplight Therapeutics in the fourth quarter worth about $205,000.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maplight Therapeutics in a research report on Monday, July 13th. Lifesci Capital raised Maplight Therapeutics to a “strong-buy” rating in a research note on Thursday, May 14th. Stifel Nicolaus lifted their price objective on Maplight Therapeutics from $28.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, June 1st. Needham & Company LLC boosted their target price on Maplight Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Friday, July 10th. Finally, Craig Hallum restated a “buy” rating and set a $25.00 target price on shares of Maplight Therapeutics in a report on Tuesday, July 28th. Four equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Maplight Therapeutics currently has an average rating of “Buy” and a consensus price target of $34.42.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.